CLINICAL TRIALS PROFILE FOR LORATADINE; PSEUDOEPHEDRINE SULFATE
✉ Email this page to a colleague
All Clinical Trials for loratadine; pseudoephedrine sulfate
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00837915 ↗ | Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions | Completed | Ranbaxy Laboratories Limited | N/A | 2002-06-01 | The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets, in a fully replicated design, under fasting conditions. |
NCT00845546 ↗ | Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions | Completed | Ranbaxy Laboratories Limited | N/A | 2002-06-01 | The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Schering (Claritin-D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets, in a fully replicated design, under fed conditions. |
NCT01055756 ↗ | Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis | Withdrawn | Azidus Brasil | Phase 3 | 2010-01-01 | The primary objective of this study is to evaluate the clinical efficacy of the drug Cloratadd D ® (loratadine + pseudoephedrine sulfate - EMS S/A) compared to the drug Claritin D ® (loratadine + pseudoephedrine sulfate - Schering Plough) in patients with allergic rhinitis by quantification of the scores of clinical parameters (signs and symptoms) and laboratory (nasal flow) down through time. |
NCT03443843 ↗ | A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure | Completed | Bayer | Phase 4 | 2018-02-21 | The purpose of the study is to evaluate changes in nasal airflow caused by loratadine 5 mg/pseudoephedrine sulfate 120 mg (Claritin D) tablet and fluticasone propionate 50 mcg per spray nasal spray (Flonase) in subjects suffering from nasal congestion and other allergy symptoms. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for loratadine; pseudoephedrine sulfate
Condition Name
Clinical Trial Locations for loratadine; pseudoephedrine sulfate
Trials by Country
Clinical Trial Progress for loratadine; pseudoephedrine sulfate
Clinical Trial Phase
Clinical Trial Sponsors for loratadine; pseudoephedrine sulfate
Sponsor Name